On Sept. 14, AMCP joined a Medicaid stakeholder letter urging Congress to include language that requires 12-month continuous eligibility for children on Medicaid and the Children’s Health Insurance Program (CHIP) in the reconciliation bill.
Letter requests an immediate amendment to the PREP Act declaration on COVID-19, which would allow pharmacists to order and administer REGEN-COV and future authorized products for the treatment of COVID-19.
On July 28, AMCP signed a Medicare Part D stakeholder letter urging HHS to extend the Enhanced Medication Therapy Management (EMTM) Model which is currently set to expire on December 31, 2021.
On July 26, AMCP joined other health care organizations in a joint statement in support of COVID-19 Vaccine mandates for all workers in health and long-term care.
AMCP submitted comments on a Office of Management and Budget request for information on advancing equity in underserved communities through government.
On June 14, AMCP submitted comments on the Medicare Part D Medication Therapy Management Program's Standardized Format for the comprehensive medication review.
On May 25, AMCP joined Medicare stakeholder organizations in thanking Congressional members for introducing the Pharmacy and Medically Underserved Areas Enhancement Act (H.R. 2759/S.1362).
On April 19, AMCP submitted joint recommendations to CMS on Medicare Advantage enrollees seeking COVID-19 vaccine without their Original Medicare card. CMS is recommended to present clear guidance to all vaccination sites and providers and instruct MACs to provide assistance to providers to ensure vaccine administration is accurately reimbursed and entered into the COVAX portal.
AMCP submitted a letter on the reopened comment period for the Medicaid Coverage of Innovative Technologies rule, which created a pathway for fast national Medicare coverage of innovative technologies, including digital therapeutics.
On March 16, AMCP joined Medicare stakeholders in urging House and Senate leadership to swiftly repeal the 2020 Medicare Part D rebate rule using Congressional Review Act authority.
On Feb. 18, AMCP joined the Modern Medicaid Alliance in urging Congress to strengthen the Medicaid program in the next COVID response bill by increasing the Federal Medical Assistance Percentage (FMAP) by at least 12 percentage points.
AMCP submitted comments to CMS on the Most Favored Nation Model rule, expressing our significant concerns that the model would negatively impact patient access to needed medications.
Read AMCP's summary of how the inauguration of the Biden administration may lead to changes to reglatory actions taken at the end of the Trump administration.
In a January 15th letter to President-elect Joseph R. Biden, AMCP shared its priority issues related to the COVID-19 pandemic and managed care pharmacy.
On Jan. 5, AMCP joined the Pharmacy Health Information Technology (PHIT) Collaborative and national pharmacy stakeholders in submitting comments to CMS on its Medicaid prior authorization proposed rule. AMCP supports expanding use of electronic prior authorizations, removing barriers to health information technology adoption and providing patients and providers with information regarding prior authorization decisions.
On Dec. 21, CMS published a Final Rule to support state flexibility to enter into value-based purchasing arrangements (VBPs) with drug manufacturers, and to allow manufacturers with qualifying VBPs to report multiple best price points for a single dosage form and strength of a covered outpatient drug. The final rule is effective on Jan. 1, 2022.